Author

Andrew J. Thorpe 1

1 Pfizer Inc,Collegeville,United States

Item-level improvements in inflammatory bowel disease questionnaire scores in patients with ulcerative colitis treated with tofacitinib induction therapy

Marla C. Dubinsky, Marco DiBonaventura, Haiyun Fan, Andrew G. Bushmakin, Joseph C. Cappelleri, Eric Maller, Andrew J. Thorpe, Leonardo Salese, Julian Panés

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Nervin Lawendy, Gary S. Friedman, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, Amy Marren, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 5.5 years of treatment

Gary R. Lichtenstein, Edward V. Loftus Jr., Arif Soonasra, Nervin Lawendy, Gary Chan, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Stuart Bloom

TIME TO LOSS OF EFFICACY FOLLOWING TOFACITINIB INTERRUPTION IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM OCTAVE SUSTAIN

Marla C. Dubinsky, Kofi Clarke, Jochen G. Klaus, Yoram Bouhnik, Arif Soonasra, Andrew J. Thorpe, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Nervin Lawendy, Chinyu Su

Tofacitinib for the treatment of ulcerative colitis: an update on the analysis of malignancy rates from the UC clinical programme

Gary R. Lichtenstein, Matthew A. Ciorba, Gerhard Rogler, Daniel Quirk, Andrew J. Thorpe, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Julian Panés

Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates in the tofacitinib ulcerative colitis clinical programme

Kevin L. Winthrop, Edward V. Loftus Jr., Daniel C. Baumgart, Leonardo Salese, Andrew J. Thorpe, Nervin Lawendy, Gary Chan, Ronald D. Pedersen, Walter Reinisch

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY

Gary R. Lichtenstein, Edward V Loftus Jr, Stuart Bloom, Nervin Lawendy, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 4.9 YEARS OF TREATMENT

Gary R. Lichtenstein, Edward V. Loftus Jr., Stuart Bloom, Nervin Lawendy, Gary Chan, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Item 1 - 9 / 9
1